Epoprostenol — Discount Pricing

Other medications in Heart & Cardiovascular

• Eprosartan
• Evolocumab
• Ezetimibe
• Felodipine
• Fenofibrate
• Flecainide
• Fluvastatin
• Fosinopril

About Epoprostenol

Epoprostenol is a critical medication used to manage severe forms of Pulmonary Arterial Hypertension (PAH), a life-threatening condition. Its continuous administration and specialized nature often lead to significant costs. At TheDrugClub, we understand the importance of accessing essential medications like epoprostenol, and we're dedicated to helping our members find affordable solutions to manage their health.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Epoprostenol is approved for (FDA label)

Epoprostenol for Injection is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III–IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases. Epoprostenol for Injection is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III–IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: January 6, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Epoprostenol (FDA label)

Epoprostenol for Injection contains epoprostenol sodium equivalent to 0.5 mg (500,000 ng) or 1.5 mg (1,500,000 ng) epoprostenol and is supplied as a sterile lyophilized material in a 10 mL vial. Injection: 10 mL single-dose vial with 0.5 mg (500,000 ng) or 1.5 mg (1,500,000 ng) Epoprostenol for Injection. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 47f64fcd-cbf7-457a-9548-661fb10ff7e0. SPL document ID: 8b45ebae-92d6-4a3b-a559-115c66a8352a. Label effective date: January 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Epoprostenol (FDA label)

• Most common adverse reactions during: - Dose Initiation and Escalation: Nausea, vomiting, headache, hypotension, flushing, chest pain, anxiety, dizziness, bradycardia, dyspnea, abdominal pain, musculoskeletal pain, and tachycardia ( 6.1 ) - Chronic Dosing: Headache, jaw pain, flushing, diarrhea, nausea and vomiting, flu-like symptoms, and anxiety/nervousness ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Gland Pharma Limited at 866-770-7144 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 47f64fcd-cbf7-457a-9548-661fb10ff7e0. SPL document ID: 8b45ebae-92d6-4a3b-a559-115c66a8352a. Label effective date: January 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Epoprostenol (FDA label)

A large study evaluating the effect of epoprostenol on survival in NYHA Class III and IV patients with congestive heart failure due to severe left ventricular systolic dysfunction was terminated after an interim analysis of 471 patients revealed a higher mortality in patients receiving epoprostenol plus conventional therapy than in those receiving conventional therapy alone. The chronic use of Epoprostenol for Injection in patients with congestive heart failure due to severe left ventricular systolic dysfunction is therefore contraindicated. Some patients with pulmonary hypertension have developed pulmonary edema during dose initiation, which may be associated with pulmonary veno-occlusive disease. Epoprostenol for Injection should not be used chronically in patients who develop pulmonary edema during dose initiation. Epoprostenol for Injection is also contraindicated in patients with known hypersensitivity to the drug or to structurally related compounds.

Source: FDA prescribing information (DailyMed). Set ID: 47f64fcd-cbf7-457a-9548-661fb10ff7e0. SPL document ID: 8b45ebae-92d6-4a3b-a559-115c66a8352a. Label effective date: January 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Epoprostenol (FDA label)

Do not abruptly lower the dose or withdraw dosing. All dosing initiation and changes should be closely monitored. ( 5.2 , 5.3 ) 5.1 Dose Initiation Epoprostenol for Injection is a potent pulmonary and systemic vasodilator. Initiate Epoprostenol for Injection in a setting with adequate personnel and equipment for physiologic monitoring and emergency care. Dose initiation has been performed during right heart catheterization and without cardiac catheterization. During dose initiation, asymptomatic increases in pulmonary artery pressure coincident with increases in cardiac output occurred rarely. In such cases, consider dose reduction, but such an increase does not imply that chronic treatment is contraindicated. 5.2 Chronic Use and Dose Adjustment During chronic use, deliver Epoprostenol for Injection continuously on an ambulatory basis through a permanent indwelling central venous catheter.

Source: FDA prescribing information (DailyMed). Set ID: 47f64fcd-cbf7-457a-9548-661fb10ff7e0. SPL document ID: 8b45ebae-92d6-4a3b-a559-115c66a8352a. Label effective date: January 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Epoprostenol (FDA label)

Additional reductions in blood pressure may occur when Epoprostenol for Injection is administered with diuretics, antihypertensive agents, or other vasodilators. When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for Epoprostenol for Injection to increase the risk of bleeding. However, patients receiving infusions of epoprostenol in clinical trials were maintained on anticoagulants without evidence of increased bleeding. In clinical trials, epoprostenol was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen. In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with epoprostenol was initiated, apparent oral clearance values for furosemide (n=23) and digoxin (n=30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87. The change in furosemide clearance value is not likely to be clinically significant.

Source: FDA prescribing information (DailyMed). Set ID: 47f64fcd-cbf7-457a-9548-661fb10ff7e0. SPL document ID: 8b45ebae-92d6-4a3b-a559-115c66a8352a. Label effective date: January 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.